May 18, 2016

Systematic Design and Development of the Q2 Solutions Comprehensive Cancer Panel

A Case Study in Iterative Design and Validation
Presented at Precision Medicine Congress on September 15, 2015, this presentation describes Q2 Solutions Comprehensive Cancer Panel content, how it was selected and design considerations – as well as performance characteristics and the impact of bioinformatic enhancement. This presentation will also highlight considerations in using the panel for genomic profiling of cancer patients. 

Download the presentation to learn more.

Thomas Halsey, Ph.D.,Associate Director, Genomic Research and Development
Victor Weigman, Ph.D. Associate Director, Translational Genomics

Related Services:
Q2 Solutions Comprehensive Cancer Panel

Targeted sequencing assay

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Read More